Skip to search formSkip to main contentSkip to account menu

YHO-13351

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Acrylonitrile
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
BACKGROUND/AIM The aim of this study was to determine the efficacy of the combination of irinotecan and newly-synthesized ABCG2… 
2011
2011
Preclinical Development Novel Acrylonitrile Derivatives , YHO-13177 and YHO-13351 , Reverse BCRP / ABCG 2-Mediated Drug Resistance In Vitro and In Vivo
Breast cancer resistance protein (BCRP/ABCG2) confers resistance to anticancer drugs such as 7-ethyl-10hydroxycamptothecin (SN-38… 
2007
2007
YHO-13351, a novel acrylonitrile derivative, reverses BCRP/ABCG2-mediated drug resistance in vitro and in vivo
A182 Background: Breast cancer resistance protein (BCRP), also called ABCG2, has been shown to confer resistance to anticancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)